This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Membrane-associated guanylate kinase WW and PDZ domain containing 3 (MAGI3); protein kinase Bγ (PKBG; AKT3)	<p>Patient sample and cell culture studies suggest AKT (PKB; PKBA; AKT1) inhibitors could help treat breast cancers expressing the MAGI3-AKT3 fusion protein. Genome sequencing and computational analysis identified a MAGI3-AKT3 fusion protein in 5 of 72 triple-negative tumor samples. In cell culture, expression of MAGI3-AKT3 led to excess phosphorylation of AKT substrates, which was inhibited by a pan-AKT inhibitor. Next steps include additional cellular and animal model experiments.</p> <p>At least 11 companies have AKT inhibitors in development from Phase I to Phase III trials for various types of cancer.</p> <p>SciBX 5(27); doi:10.1038/scibx.2012.699 Published online July 12, 2012</p>	Patent application filed; unlicensed	<p>Banerji, S. <i>et al. Nature</i>; published online June 20, 2012; doi:10.1038/nature11154 Contact: Matthew Meyerson, Dana-Farber Cancer Institute, Boston, Mass. e-mail: matthew_meyerson@dfci.harvard.edu</p>